AXSM
Income statement / Annual
Last year (2023), Axsome Therapeutics, Inc.'s total revenue was $270.60 M,
an increase of 440.80% from the previous year.
In 2023, Axsome Therapeutics, Inc.'s net income was -$239.24 M.
See Axsome Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$270.60 M
|
$50.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$26.07 M |
$5.20 M |
$1.16 M |
$77,718.00 |
$37,330.00 |
$48,935.00 |
$42,557.00 |
$20,484.00 |
$3,542.00 |
$0.00 |
| Gross Profit |
$244.54 M |
$44.84 M |
-$1.16 M |
-$77,718.00 |
-$37,330.00 |
-$48,935.00 |
-$42,557.00 |
-$20,484.00 |
-$3,542.00 |
$0.00 |
| Gross Profit Ratio |
0.9 |
0.9 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$97.94 M
|
$57.95 M
|
$58.06 M
|
$70.24 M
|
$53.65 M
|
$23.50 M
|
$19.96 M
|
$21.20 M
|
$6.78 M
|
$4.28 M
|
| General & Administrative
Expenses |
$222.82 M
|
$123.95 M
|
$66.65 M
|
$28.90 M
|
$13.60 M
|
$9.35 M
|
$7.21 M
|
$6.34 M
|
$2.42 M
|
$1.39 M
|
| Selling & Marketing
Expenses |
$100.30 M
|
$35.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$323.12 M
|
$159.25 M
|
$66.65 M
|
$28.90 M
|
$13.60 M
|
$9.35 M
|
$7.21 M
|
$6.34 M
|
$2.42 M
|
$1.39 M
|
| Other Expenses |
$55.29 M |
$4.14 M |
$0.00 |
-$53,578.00 |
-$139,448.00 |
$217,418.00 |
$207,114.00 |
$474,279.00 |
$0.00 |
-$184,139.00 |
| Operating Expenses |
$476.36 M |
$221.34 M |
$124.71 M |
$99.09 M |
$67.11 M |
$32.63 M |
$26.96 M |
$27.07 M |
$9.20 M |
$5.49 M |
| Cost And Expenses |
$502.43 M |
$226.54 M |
$124.71 M |
$99.09 M |
$67.11 M |
$32.63 M |
$26.96 M |
$27.07 M |
$9.20 M |
$5.49 M |
| Interest Income |
$0.00 |
$7.33 M |
$5.70 M |
$2.57 M |
$1.24 M |
$0.00 |
$0.00 |
$0.00 |
$914,952.00 |
$2.23 M |
| Interest Expense |
$6.45 M |
$7.33 M |
$5.70 M |
$2.57 M |
$1.24 M |
$1.13 M |
$1.34 M |
$132,424.00 |
$914,952.00 |
$2.23 M |
| Depreciation &
Amortization |
$6.83 M
|
$5.56 M
|
$1.16 M
|
$77,718.00
|
$37,330.00
|
$48,935.00
|
$42,557.00
|
$20,484.00
|
$3,542.00
|
$2.93 M
|
| EBITDA |
-$224.99 M
|
-$174.23 M
|
-$123.55 M
|
-$99.06 M
|
-$67.21 M
|
-$32.58 M
|
-$27.77 M
|
-$27.52 M
|
-$9.19 M
|
-$2.74 M
|
| EBITDA Ratio |
-0.83 |
-3.42 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-0.86
|
-3.53
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$6.45 M
|
-$7.33 M
|
-$5.70 M
|
-$3.81 M
|
-$1.24 M
|
$1.66 M
|
-$1.78 M
|
$341,855.00
|
-$1.36 M
|
-$328,532.00
|
| Income Before Tax |
-$238.28 M |
-$187.13 M |
-$130.40 M |
-$102.90 M |
-$68.35 M |
-$30.97 M |
-$28.94 M |
-$27.20 M |
-$10.56 M |
-$6.00 M |
| Income Before Tax Ratio
|
-0.88
|
-3.74
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$960,000.00 |
$10.63 M |
$4.54 M |
$2.49 M |
$1.34 M |
$3.01 M |
$1.30 M |
$586,219.00 |
$1.36 M |
-$2.42 M |
| Net Income |
-$239.24 M |
-$197.77 M |
-$134.94 M |
-$105.39 M |
-$69.69 M |
-$30.97 M |
-$28.94 M |
-$27.20 M |
-$10.56 M |
-$6.00 M |
| Net Income Ratio |
-0.88 |
-3.95 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-5.27 |
-4.86 |
-3.59 |
-2.83 |
-2.05 |
-1.15 |
-1.27 |
-1.42 |
-0.88 |
-0.47 |
| EPS Diluted |
-5.27 |
-4.86 |
-3.59 |
-2.83 |
-2.05 |
-1.15 |
-1.27 |
-1.42 |
-0.88 |
-0.47 |
| Weighted Average Shares
Out |
$45.43 M
|
$40.66 M
|
$37.62 M
|
$37.21 M
|
$34.02 M
|
$26.88 M
|
$22.76 M
|
$19.15 M
|
$11.95 M
|
$12.72 M
|
| Weighted Average Shares
Out Diluted |
$45.43 M
|
$40.66 M
|
$37.62 M
|
$37.21 M
|
$34.02 M
|
$26.88 M
|
$22.76 M
|
$19.15 M
|
$11.95 M
|
$12.72 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
